Ingevity Corp
NGVT- Exchange
- NYSE
- Industry
- Chemicals & Allied Products
- SEC CIK
- 0001653477
In the last 90 days, Ingevity Corp insiders filed 0 open-market purchases and 2 sales; 318 institutions reported holding it in 13F filings for Q2 2026, worth $2.62B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:55 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Jan 16, 2025 | Feb 21, 2024 | Feb 27, 2023 | Feb 23, 2022 |
| Revenue | $1.17B | $1.41B | $1.69B | $1.67B | $1.39B |
| Cost of revenue | $706.1M | $951.7M | $1.22B | $1.10B | $878.7M |
| Gross profit | $461.5M | $454.7M | $471.9M | $570.1M | $512.8M |
| Research and development | $28.4M | $28.1M | $31.8M | $30.3M | $26.3M |
| Selling, general and administrative | $171.2M | $166.7M | $183.7M | $198.8M | $179.3M |
| Operating income | $418.7M | $369.0M | $396.8M | $452.6M | $422.2M |
| Interest expense | $78.3M | $97.8M | $93.3M | $61.8M | $51.7M |
| Income tax | $8.20M | -$105.3M | -$4.70M | $58.0M | $44.7M |
| Net income | -$167.1M | -$430.3M | -$5.40M | $211.6M | $118.1M |
| EPS, basic | $-4.61 | $-11.85 | $-0.15 | $5.54 | $2.97 |
| EPS, diluted | $-4.61 | $-11.85 | $-0.15 | $5.50 | $2.95 |
| Weighted shares, basic | 36.2M | 36.3M | 36.5M | 38.2M | 39.8M |
| Weighted shares, diluted | 36.2M | 36.3M | 36.5M | 38.5M | 40.1M |
| Margins and growth | |||||
| Gross margin | 39.5% | 32.3% | 27.9% | 34.2% | 36.9% |
| Operating margin | 35.9% | 26.2% | 23.5% | 27.1% | 30.3% |
| Net margin | -14.3% | -30.6% | -0.3% | 12.7% | 8.5% |
| Revenue growth, year over year | −17.0% | −16.9% | +1.4% | +19.9% | +14.4% |
| Net income growth, year over year | – | – | −102.6% | +79.2% | −34.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Jan 16, 2025 | Feb 21, 2024 | Feb 27, 2023 | Feb 23, 2022 |
| Cash and equivalents | $78.1M | $68.0M | $95.9M | $76.7M | $275.4M |
| Inventory | $186.0M | $226.8M | $308.8M | $335.0M | $241.2M |
| Total current assets | $454.2M | $493.2M | $658.6M | $679.0M | $724.9M |
| Property, plant and equipment | $608.1M | $658.9M | $762.2M | $798.6M | $719.7M |
| Goodwill | $4.30M | $175.2M | $527.5M | $518.5M | $442.0M |
| Intangible assets | $176.1M | $278.8M | $336.1M | $404.8M | $337.6M |
| Total assets | $1.65B | $2.02B | $2.62B | $2.74B | $2.47B |
| Accounts payable | $92.0M | $94.5M | $158.4M | $174.8M | $125.8M |
| Short-term debt | $47.1M | $61.3M | $84.4M | $900.0K | $19.6M |
| Total current liabilities | $341.3M | $264.1M | $362.9M | $303.5M | $268.9M |
| Total liabilities | $1.62B | $1.83B | $1.99B | $2.04B | $1.80B |
| Shareholders' equity | $29.7M | $195.2M | $631.4M | $698.3M | $673.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Jan 16, 2025 | Feb 21, 2024 | Feb 27, 2023 | Feb 23, 2022 |
| Operating cash flow | $331.2M | $128.6M | $205.1M | $313.1M | $293.0M |
| Capital expenditures | $57.7M | $77.6M | $109.8M | $142.5M | $103.8M |
| Free cash flow | $273.5M | $51.0M | $95.3M | $170.6M | $189.2M |
| Depreciation and amortization | $106.4M | $108.3M | $122.8M | $108.8M | $109.9M |
| Stock-based compensation | $18.3M | $11.9M | $10.6M | $16.1M | $12.3M |
| Share buybacks | $56.3M | $0 | $92.1M | $145.2M | $109.4M |
| Investing cash flow | -$57.5M | -$79.5M | -$77.3M | -$553.9M | -$140.6M |
| Financing cash flow | -$252.2M | -$70.2M | -$99.9M | $48.1M | -$133.1M |
| Net change in cash | $26.0M | -$25.3M | $27.6M | -$198.7M | $17.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.6% | 0.8% | 0.6% | 1.0% | 0.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.